CN105796803A - Traditional Chinese medicine composition for treating and preventing prostatic diseases and its preparation method and use - Google Patents
Traditional Chinese medicine composition for treating and preventing prostatic diseases and its preparation method and use Download PDFInfo
- Publication number
- CN105796803A CN105796803A CN201410836220.8A CN201410836220A CN105796803A CN 105796803 A CN105796803 A CN 105796803A CN 201410836220 A CN201410836220 A CN 201410836220A CN 105796803 A CN105796803 A CN 105796803A
- Authority
- CN
- China
- Prior art keywords
- extract
- lycopersici esculenti
- saw palmetto
- soybean
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 claims abstract description 99
- 239000000203 mixture Substances 0.000 claims abstract description 64
- 240000006661 Serenoa repens Species 0.000 claims abstract description 60
- 235000005318 Serenoa repens Nutrition 0.000 claims abstract description 60
- 235000020712 soy bean extract Nutrition 0.000 claims abstract description 53
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 18
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 18
- 201000007094 prostatitis Diseases 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 6
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims abstract description 3
- 240000003768 Solanum lycopersicum Species 0.000 claims abstract description 3
- 239000010018 saw palmetto extract Substances 0.000 claims description 54
- 239000007901 soft capsule Substances 0.000 claims description 34
- 238000000605 extraction Methods 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 21
- 239000008187 granular material Substances 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 239000003643 water by type Substances 0.000 claims description 4
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 3
- 229940068682 chewable tablet Drugs 0.000 claims description 3
- 239000007919 dispersible tablet Substances 0.000 claims description 3
- 238000009413 insulation Methods 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000012501 chromatography medium Substances 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 230000001351 cycling effect Effects 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000000385 dialysis solution Substances 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 235000021022 fresh fruits Nutrition 0.000 claims description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 2
- 235000008696 isoflavones Nutrition 0.000 claims description 2
- 239000001751 lycopene Substances 0.000 claims description 2
- 235000012661 lycopene Nutrition 0.000 claims description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 2
- 229960004999 lycopene Drugs 0.000 claims description 2
- 238000001471 micro-filtration Methods 0.000 claims description 2
- 229930189775 mogroside Natural products 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 208000025844 Prostatic disease Diseases 0.000 abstract 2
- 241001409321 Siraitia grosvenorii Species 0.000 abstract 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229940127554 medical product Drugs 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 42
- 210000002307 prostate Anatomy 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 108010010803 Gelatin Proteins 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 239000002775 capsule Substances 0.000 description 15
- 239000008273 gelatin Substances 0.000 description 15
- 229920000159 gelatin Polymers 0.000 description 15
- 235000019322 gelatine Nutrition 0.000 description 15
- 235000011852 gelatine desserts Nutrition 0.000 description 15
- 239000011162 core material Substances 0.000 description 13
- -1 dibenzylatiooluene Chemical compound 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 10
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- 201000001514 prostate carcinoma Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 7
- 102000013563 Acid Phosphatase Human genes 0.000 description 7
- 108010051457 Acid Phosphatase Proteins 0.000 description 7
- 235000010418 carrageenan Nutrition 0.000 description 7
- 229920001525 carrageenan Polymers 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 6
- 206010025482 malaise Diseases 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 5
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 5
- 229960002216 methylparaben Drugs 0.000 description 5
- 239000000473 propyl gallate Substances 0.000 description 5
- 235000010388 propyl gallate Nutrition 0.000 description 5
- 229940075579 propyl gallate Drugs 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 5
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000019485 Safflower oil Nutrition 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000003813 safflower oil Substances 0.000 description 4
- 235000005713 safflower oil Nutrition 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 240000008415 Lactuca sativa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 3
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 3
- 235000001046 cacaotero Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 150000002333 glycines Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000012045 salad Nutrition 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229960001712 testosterone propionate Drugs 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- 240000001592 Amaranthus caudatus Species 0.000 description 2
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 235000003935 Hippophae Nutrition 0.000 description 2
- 241000229143 Hippophae Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004178 amaranth Substances 0.000 description 2
- 235000012735 amaranth Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006229 carbon black Substances 0.000 description 2
- 239000007766 cera flava Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940073505 ethyl vanillin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229940072254 proscar Drugs 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000004574 high-performance concrete Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medical product and a production method thereof and discloses a traditional Chinese medicine composition for treating and preventing prostatic diseases such as prostatic hyperplasia, prostatitis and prostatic cancer. The traditional Chinese medicine composition comprises sabal extract, soybean extract and tomato extract and can also comprise siraitia grosvenorii extract. The invention provides a preparation and a preparation method thereof. The traditional Chinese medicine composition can be used as a health product for treating prostatic diseases and greatly improves male living quality. The invention relates to the preparation method of the preparation. Though method improvement, ingredients produce synergism.
Description
Technical field
The present invention relates to medicinal preparation and production method thereof, it it is a kind of Chinese medicine composition treating and preventing the prostatosis such as prostatic hyperplasia, prostatitis, carcinoma of prostate, comprise Saw Palmetto P.E, soybean extract, Fructus Lycopersici esculenti extract, Fructus Momordicae extract can be contained, thering is provided its preparation and preparation technology thereof, said composition is particularly to being used for keep healthy prostate, raising male's quality of life simultaneously.
Background technology
Prostatosis is commonly encountered diseases and the frequently-occurring disease of male, common disease such as prostatitis, prostatic hyperplasia, carcinoma of prostate.Prostatitis is the commonly encountered diseases of Urology Surgery, accounts for first place in Urology Surgery male patient's the right side of fifty, shows as chronic, recurrent process more.Prostatitis main pathogenic is pathogenic infection, and pathogen invades prostate with urine, causes infecting.Pathological anatomy confirms that prostatitis pathological changes is typically limited to peripheral zone, and glandular tube is opened on Posterior urethral with uroflow vertical line is reverse herein, easily causes urine reflux, and central zone and transitional zone glandular tube trend are consistent with uroflow direction, are not susceptible to infect.Research also finds that prostate is not only had stimulation by the urate of urine, also precipitable one-tenth calculus, blocks glandular tube, as the protection place of antibacterial.These are it is found that illustrate the coexpress that prostatitis syndrome is multiple disease in fact, and complicated clinical manifestation is changeable, can produce various complication.
Additionally China has stepped into aging society, and prostatic hyperplasia is commonly encountered diseases and the frequently-occurring disease of elderly men.Cumulative many with population in the world senescence onset of illness.The sickness rate of prostatic hyperplasia was incremented by with the age, and cities and towns sickness rate is higher than rural area, and race difference also affects hyperplasia degree.Its symptom increases (especially night), dysuria with number of micturitions, uroflow attenuates as main feature.As climate change, fatigue, drink, the inducement such as sexual life or infection, very easily cause urine retention, even urine can not arranged completely, causes considerable distress.According to statistics, it is 70% that the elderly men sickness rate of more than 50 years old there are about the elderly men prostatic hyperplasia sickness rate in 30-50%, 70-90 year, and more than 80 years old there are about more than 90% suffers from this disease, domestic statistics, prostatic hyperplasia accounts for 8% the 11% of Urology Surgery inpatient.
Carcinoma of prostate refers to that generation is at prostatic epithelial malignancy.Within 2012, China's tumor registration area prostate-cancer incidence is 9.92/10 ten thousand, the 6th of row male malignancy sickness rate.Age of onset was in reduced levels before 55 years old, gradually rose after 55 years old, and sickness rate increases with advancing age, and the peak age is 70-80 year.Carcinoma of prostate is also kinds of tumor in western countries, and mortality rate is high..
Thus, prostatosis has become the commonly encountered diseases affecting men's health, annoyings many male, has severely impacted their quality of life, and prostatic health care has caused the extensive concern of society.So effectively preventing and treating the prostatosis such as prostatic hyperplasia, prostatitis, carcinoma of prostate, the prostatic product that keeps healthy has great social meaning, it will be greatly improved the quality of life of male.
Summary of the invention
The invention provides a kind of compositions treating and preventing prostatic hyperplasia, prostatitis, carcinoma of prostate, comprise Saw Palmetto P.E, Fructus Lycopersici esculenti extract, soybean extract, it is possible to containing Fructus Momordicae extract.Present invention also offers said composition preparation and its production and use.
The invention provides a kind of compositions, be used for treating and preventing prostatic hyperplasia, prostatitis, carcinoma of prostate, it is characterised in that it comprises following raw material: Saw Palmetto P.E 200-800 part, Fructus Lycopersici esculenti extract 30-180 part, soybean extract 30-90 part.It is preferred that Saw Palmetto P.E is 320 parts, Fructus Lycopersici esculenti extract is 50 parts, and soybean extract is 62.5 parts, and more preferably a compositions is containing Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg.
Present invention also offers a kind of compositions, it is characterized in that it comprises following raw material: Saw Palmetto P.E 200-800 part, Fructus Lycopersici esculenti extract 30-180 part, soybean extract 30-90 part, Fructus Momordicae extract 10-40 part can be contained, it is preferred that Saw Palmetto P.E is 600 parts, Fructus Lycopersici esculenti extract is 120 parts, soybean extract is 60 parts, Fructus Momordicae extract 20 parts, more preferably a compositions is containing Saw Palmetto P.E 600mg, Fructus Lycopersici esculenti extract 120mg, soybean extract 60mg, Fructus Momordicae extract 20mg.
Saw Palmetto P.E of the present invention is prepared gained by following methods:
After sabal raw material is cleaned, ambient ground；Cross 40-60 mesh sieve, weigh the sabal raw material pulverized in advance in extraction kettle, extraction kettle, separating still are respectively heated, reach to set extraction kettle 40 DEG C, the temperature that separating still is 25 DEG C, CO2 enters liquefaction tank liquor through gas purifier, extraction kettle squeezed into by preheated device, depurator, extraction kettle and separating still are boosted, after reaching required extraction kettle pressure 20MPa, separating still pressure 5MPa, closes dioxide bottle, start the cycle over extraction, collecting separating still discharging, dry to obtain Saw Palmetto P.E, in described Saw Palmetto P.E, content of fatty acid is 45%.
Fructus Lycopersici esculenti extract of the present invention is prepared gained by following methods:
Raw tomatoes material is pulled an oar, and squeeze and filter, it is dried by vacuum freezing effect, ambient ground, cross 20-40 mesh sieve, powder and hexane weight ratio (1:2) are put into extracting tank and forms intimate mixing, the dissolution from hexane of the pigment in raw material, separating hexane, the raw material of pretreatment enters extraction kettle；CO2 enters liquefaction tank liquor through gas purifier, then extraction kettle is squeezed into by the preheated device of high-pressure plunger pump, depurator, extraction kettle boosts to 30MPa and makes supercritical fluid, set separating still pressure 5MPa, CO2 enters liquefaction groove cycling extraction after device purified separating still, and extract is released from the bottom of separating still, collects separating still discharging, drying to obtain Fructus Lycopersici esculenti extract, in described Fructus Lycopersici esculenti extract, the content of lycopene is 10%.
Soybean extract of the present invention is prepared gained by following methods:
By Semen sojae atricolor ungrease treatment, with pulverizer, totally dry defatted soybean is pulverized, cross 20-40 mesh sieve, obtain coarse powder；Take and pulverize dry Semen sojae atricolor, add 70% ethanol (volume/weight) of 15 times amount, extract 1 hour 50 DEG C of room temperatures, filter, repeat 2 times, united extraction liquid, employing polyamide is chromatography media, and column chromatography is to extract refining, acetone extract eluent, dry extract, obtains soybean extract, and the content of described Isoflavone in Extract of Soybean is 40%.
Fructus Momordicae extract of the present invention is prepared gained by following methods:
First Fructus Momordicae fresh fruit is smashed to pieces, throw to extractor.Adding 3 times amount deionized waters for 1st time, heating, to boiling, is incubated 2h, starts timing from boiling, feed liquid is put into storage tank；Add 3 times amount deionized waters, ebuillition of heated for 2nd time, after insulation 2h, feed liquid is merged with the 1st feed liquid.Being poured into by the extracting solution of merging in concentrator and carry out concentrating under reduced pressure, temperature controls below 60 DEG C, and vacuum degree control, more than 0.08, is recycled to concentrated solution and raw material ratio when being 2.5:1, stops heating, release concentrated solution, cooling.Mateiral pump on microfiltration equipment is started, in concentrated solution suction tube type filter membrance, force (forcing) pump will be started, regulate pressure to 0.2MPa, collect the filtrate through tube type filter membrance, the solution to be concentrated water-dialyzing by 0.5 times will be added time complete, the dialysis solution being collected by, merging filtrate.The filtrate of collection is poured in the storage tank of ultrafiltration apparatus, open the force (forcing) pump of ultrafiltration apparatus, regulate pressure at 1MPa, filtrate retains, by passing through, the film that relative molecular mass is 40000, collect through filtrate, when filtrate is passed through less, slowly add the water-dialyzing of people 0.5 times, collect the dialysis filtrate passed through, merging filtrate.Filtrate being carried out spray drying, obtains Fructus Momordicae extract, in described Fructus Momordicae extract, mogroside content is 25%.
Present invention also offers a kind of composite preparation and preparation technology thereof, said preparation can effectively prevent and treat prostatic hyperplasia, prostatitis, carcinoma of prostate, and keep healthy prostate, thus being greatly improved the quality of life of male.
Preparation of the present invention is including but not limited to ordinary tablet, chewable tablet, buccal tablet, dispersible tablet, oral liquid, granule, powder, soft capsule, unguentum and tincture.
One of technical scheme is achieved like this: a kind of preparation, it is mainly composed of: Saw Palmetto P.E 200-800 part, Fructus Lycopersici esculenti extract 30-180 part, soybean extract 30-90 part.It is preferred that Saw Palmetto P.E is 320 parts, Fructus Lycopersici esculenti extract is 50 parts, and soybean extract is 62.5 parts, and more preferably a preparation main component is containing Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg.Preparation can contain the diluent of stabilizer and convention amount.Can select said preparation is soft capsule, and the content of above-mentioned soft capsule is mainly composed of: Saw Palmetto P.E 200-800 part, Fructus Lycopersici esculenti extract 30-180 part, soybean extract 30-90 part.It is preferred that Saw Palmetto P.E is 320 parts, Fructus Lycopersici esculenti extract is 50 parts, and soybean extract is 62.5 parts, and more preferably a soft capsule main component is containing Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg.Preparation can contain the diluent of stabilizer and convention amount.
The softgel shell of above-mentioned soft capsule by raw material weight percentage ratio can consist of the gelatin of 35% to 45%, 18% to 22% plasticizer, 0.08% to 0.11% preservative, 0 to 3% screening agent, the pigment of 0 to 1%, the correctives of 0 to 0.1% and surplus water.Above-mentioned plasticizer can be a kind of material in glycerol, sorbitol, sucrose or more than one mixture.Foregoing preservatives can be a kind of material in methyl hydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate or more than one mixture.
Above-mentioned screening agent can be a kind of material in titanium dioxide, barium sulfate, ferrum oxide, precipitated calcium carbonate or more than one mixture；Above-mentioned pigment can be lemon yellow, amaranth, carmine, cacao brown, white carbon black, light green, greyish purple in a kind of material or more than one mixing.Above-mentioned correctives can be a kind of material in bourbonal,ethyl vanillin, essential oil, Mentholum or more than one mixture.
Above-mentioned diluent can be a kind of material in Oleum Arachidis hypogaeae semen, Oleum Glycines, safflower oil, Oleum Hippophae, Oleum Camelliae, sabal oil, salad oil, Semen Maydis oil or more than one mixture.Aforementioned stable agent can be a kind of material in Cera Flava, phospholipid, Adeps caprae seu ovis, methylcellulose, ethyl cellulose, Polyethylene Glycol monostearate, glycerol or more than one mixture, and aforementioned stable agent can be a kind of material in tea polyphenols, tert-butylhydroquinone, Radix Glycyrrhizae antioxygen thing, Butylated hydroxyanisole, dibenzylatiooluene, propylgallate or more than one mixture.
The combinations thereof composition soft capsule preparation technology of the present invention is achieved like this: take the desired amount of Saw Palmetto P.E or diluent heating for dissolving stabilizer, stabilizer, adds the Fructus Lycopersici esculenti extract of requirement and stirs and make its emulsifying；Temperature controls, when 40 DEG C to 70 DEG C, add the soybean extract of requirement and stir, and adds the diluent of requirement, crosses colloid mill, obtains emulsion stable uniformly, standby；The capsule leather of above-mentioned soft capsule is standby: by the desired amount of water, plasticizer, preservative add have stirring decompressor interlayer stainless-steel pan in stir, as first liquid；Being joined by the desired amount of gelatin in the rustless steel jacketed pan filling first liquid, temperature controls constantly to reduce pressure stirring in room temperature, treats that gelatin grain expands post-heating and makes gelatin grain all melt and dissolved to 50-80 DEG C；Under stirring, add the desired amount of screening agent, pigment, continue decompression stirring 30-120 minute；Uniform melt and dissolved liquid filters, and by the compacting of filtrate insulation standing or the degassed stand-by above-mentioned soft capsule that reduces pressure: put into by capsule core material in liquid storage grain, uses rotating mould platen press compacting soft capsule；Then carry out washing ball, dry, be packaged to be present composition soft capsule.
Another technical scheme of the present invention is achieved like this: a kind of preparation, it is mainly composed of: Saw Palmetto P.E 200-800 part, Fructus Lycopersici esculenti extract 30-180 part, soybean extract 30-90 part, Fructus Momordicae extract 10-40 part, it is preferred that Saw Palmetto P.E is 600 parts, Fructus Lycopersici esculenti extract is 120 parts, soybean extract is 60 parts, Fructus Momordicae extract 20 parts, more preferably a preparation is containing Saw Palmetto P.E 600mg, Fructus Lycopersici esculenti extract 120mg, soybean extract 60mg, Fructus Momordicae extract 20mg.Preparation can contain the diluent of stabilizer and convention amount.Can select said preparation is powder, above-mentioned powder is mainly composed of: Saw Palmetto P.E 200-800 part, Fructus Lycopersici esculenti extract 30-180 part, soybean extract 30-90 part, Fructus Momordicae extract 10-40 part, it is preferred that Saw Palmetto P.E is 600 parts, Fructus Lycopersici esculenti extract is 120 parts, soybean extract is 60 parts, Fructus Momordicae extract 20 parts, more preferably a powder containing: Saw Palmetto P.E 600mg, Fructus Lycopersici esculenti extract 120mg, soybean extract 60mg, Fructus Momordicae extract 20mg, powder can contain the diluent of stabilizer and convention amount.
As required, with the Main Ingredients and Appearance of the content of above-mentioned soft capsule and capsule core material or powder and ratio thereof for foundation, the method that can produce the solid preparations such as tablet, granule, powder routinely obtains the solid dosage formss such as the tablet of the present invention, granule, powder, the method that can produce the liquid preparations such as oral liquid, injection, transfusion, Emulsion routinely obtains the liquid preparations such as the oral liquid of the present invention, injection, transfusion, Emulsion, and the method that can produce the semi-solid preparation such as unguentum, gel routinely obtains the semi-solid preparations such as the unguentum of the present invention, gel.
Present invention also offers said composition and preparation thereof and treat the purposes in prostatitic health food and food and medicine in preparation.
Present invention also offers said composition and preparation thereof the purposes in preparing the health food and food and medicine treating prostatic hyperplasia.
Present invention also offers said composition and preparation thereof the purposes in preparing the health food and food and medicine treating carcinoma of prostate.
Health food of the present invention, food, composite medicine are Saw Palmetto P.E, soybean extract, Fructus Lycopersici esculenti extract to be organically combined, it is possible to add Fructus Momordicae extract, regulate the physiological function of male comprehensively.The compatibility of raw material uses the effect having reached beyond thought Synergistic, provides a kind of new selection for health food and medicine.
Detailed description of the invention
By the examples below to present invention further instruction in addition, but do not limit the present invention in any form.
Embodiment 1
Take Saw Palmetto P.E 600g, Fructus Lycopersici esculenti extract 120g, soybean extract 60g, Fructus Momordicae extract 20g add appropriate amount of starch, mixing, granule processed, 60 DEG C dry 6 hours, granulate, mistake 20 mesh sieves, subpackage 1000 bags, obtain granule of the present invention.
Embodiment 2
Taking Saw Palmetto P.E 600g, Fructus Lycopersici esculenti extract 120g, soybean extract 60g, Fructus Momordicae extract 20g, add appropriate starch, mixing, granule processed, 60 DEG C dry 6 hours, and granulate is crossed 20 mesh sieves, is pressed into 1000, obtains ordinary tablet of the present invention.
Embodiment 3
Taking Saw Palmetto P.E 400g, Fructus Lycopersici esculenti extract 150g, soybean extract 60g, Fructus Momordicae extract 20g, add appropriate starch, mixing, granule processed, 60 DEG C dry 6 hours, and granulate is crossed 20 mesh sieves, is pressed into 1000, obtains ordinary tablet of the present invention.
Embodiment 4
Take Saw Palmetto P.E 600g, Fructus Lycopersici esculenti extract 120g, soybean extract 60g, Fructus Momordicae extract 20g, add appropriate Fructus Citri tangerinae essence, sorbitol, starch, mixing, granule processed, 60 DEG C dry 6 hours, granulate, cross 20 mesh sieves, be pressed into 1000, obtain buccal tablet of the present invention.
Embodiment 5
Taking Saw Palmetto P.E 600g, Fructus Lycopersici esculenti extract 120g, soybean extract 60g, Fructus Momordicae extract 20g, add appropriate starch, mixing, granule processed, 60 DEG C dry 6 hours, and granulate is crossed 20 mesh sieves, is pressed into 1000, obtains chewable tablet of the present invention.
Prepared by embodiment 6 oral liquid of the present invention
Take Saw Palmetto P.E 600g, Fructus Lycopersici esculenti extract 120g, soybean extract 60g, Fructus Momordicae extract 20g, add white sugar, sorbic acid, stir evenly, filter, add water to 2000ml, embedding, sterilizing, to obtain final product.
Embodiment 7
Take Saw Palmetto P.E 600g, Fructus Lycopersici esculenti extract 120g, soybean extract 60g, Fructus Momordicae extract 20g, add appropriate L-HPC, aspartame, starch, mixing, granule processed, 60 DEG C dry 6 hours, granulate, cross 20 mesh sieves, be pressed into 1000, obtain dispersible tablet.
Embodiment 8
Taking Saw Palmetto P.E 600g, Fructus Lycopersici esculenti extract 120g, soybean extract 60g, Fructus Momordicae extract 20g, add appropriate starch, mixing, granule processed, 60 DEG C dry 6 hours, and granulate is crossed 20 mesh sieves, is pressed into 1000, to obtain final product.
Embodiment 9
Taking Saw Palmetto P.E 600g, Fructus Lycopersici esculenti extract 120g, soybean extract 60g, Fructus Momordicae extract 20g, add appropriate amount of starch, mixing, granule processed, 60 DEG C dry 6 hours, fill capsule, to obtain final product.
Embodiment 10
Take Saw Palmetto P.E 600g, Fructus Lycopersici esculenti extract 120g, soybean extract 60g, Fructus Momordicae extract 20g, mixed 40 mesh sieve secondaries, subpackage 1000 bags, and to obtain final product.
Embodiment 11
The softgel shell of soft capsule contains by weight percentage: the gelatin of 35%, the glycerol of 18%, the methyl parahydroxybenzoate of 0.08% and the water of surplus；The capsule core material of this soft capsule contains: Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg, 9mg Cera Flava, the tert-butylhydroquinone (TBHQ) of 1mg, the safflower oil of surplus.
Embodiment 12
The softgel shell of soft capsule contains by weight percentage: the gelatin of 36%, the glycerol of 10%, the sorbitol of 10%, the ethylparaben of 0.10% and the water of surplus；The capsule core material of this soft capsule contains: Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg, 13mg glycerol, surplus Oleum Glycines.
Embodiment 13
The softgel shell of soft capsule contains by weight percentage: the gelatin of 37%, the sorbitol of 22%, the methyl parahydroxybenzoate of 0.11, the lemon yellow of 0.35%, the ethyl vanillin of 0.07%, the water of the titanium dioxide surplus of 1%；The capsule core material of this soft capsule contains: Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg, 45mg glycerol, the Polyethylene Glycol monostearate of 23mg, the Butylated hydroxyanisole (BHA) of 4mg, the salad oil of surplus.
Embodiment 14
The softgel shell of soft capsule contains by weight percentage: the gelatin of 38%, the sorbitol of 12%, the sucrose of 10%, the methyl parahydroxybenzoate of 0.08%, the propyl p-hydroxybenzoate of 0.02%, the amaranth of 0.1%, the barium sulfate of 0.5% and the water of surplus；The capsule core material of this soft capsule contains: Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg, 9mg tween 80, the tert-butylhydroquinone (TBHQ) of 6mg, the Semen Maydis oil of surplus.
Embodiment 15
The softgel shell of soft capsule contains by weight percentage: the gelatin of 39%, the glycerol of 19.5%, the methyl parahydroxybenzoate of 0.08%, the propyl p-hydroxybenzoate of 0.02%, 0.2% greyish purple, the ground calcium carbonate of 3% and the water of surplus；The capsule core material of this soft capsule contains: Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg, the Caulis et Folium Brassicae capitatae of surplus.
Embodiment 16
The softgel shell of soft capsule contains by weight percentage: the gelatin of 40%, the glycerol of 21%, the ethylparaben of 0.09%, the cacao brown of 0.28%, the titanium dioxide of 0.06%, the ferrum oxide of 0.68% and the water of surplus；The capsule core material of this soft capsule contains: Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg, 6mg propylgallate (PG), the Oleum Hippophae of surplus.
Embodiment 17
The softgel shell of soft capsule contains by weight percentage: the gelatin of 41%, the glycerol of 15%, the sucrose of 3%, the butyl p-hydroxybenzoate of 0.1%, the cacao brown of 0.12, the essential oil of 0.01% and the water of surplus；The capsule core material of this soft capsule contains: Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg, the salad oil of surplus.
Embodiment 18
The softgel shell of soft capsule contains by weight percentage: the gelatin of 42%, the glycerol of 21%, the methyl parahydroxybenzoate of 0.08%, the propyl p-hydroxybenzoate of 0.02%, 0.28% light green, the titanium dioxide of 0.8% and the water of surplus；The capsule core material of this soft capsule contains: Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg, the safflower oil of surplus.
Embodiment 19
The softgel shell of soft capsule contains by weight percentage: the gelatin of 43%, the glycerol of 20%, the ethylparaben of 0.1%, 0.2% light green, the barium sulfate of 0.75% and the water of surplus；The capsule core material of this soft capsule contains: Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg, 5mg Butylated hydroxyanisole (BHA), the propylgallate (PG) of 4mg, the Oleum Glycines of surplus.
Embodiment 20
The softgel shell of soft capsule contains by weight percentage: the gelatin of 44%, the glycerol of 22%, the butyl p-hydroxybenzoate of 0.08%, the white carbon black of 0.18%, the titanium dioxide of 0.65% and the water of surplus；The capsule core material of this soft capsule contains: Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg, 5mg Licorice root antioxidant, the dibenzylatiooluene (BHT) of 4mg, the Caulis et Folium Brassicae capitatae of surplus.
Embodiment 21
The softgel shell of soft capsule contains by weight percentage: the gelatin of 45%, the glycerol of 18%, the water of the greyish purple and surplus of 0.1%；The capsule core material of this soft capsule contains: Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg, 5mg glycerol, the safflower oil of surplus.
The preparation of above-described embodiment gained can by following it have been experienced that its performance:
Test example 1 prostatic hyperplasia is tested
The male cleaning grade SD rat of laboratory animal 7 week old, weight 200～250g, raising temperature 23 DEG C ± 2 DEG C, lighting hours 12h/d (7: 00～19: 00), adaptability is tested after raising one week.
Reagent proscar is purchased from Hangzhou Mo Shadong pharmaceutical Co. Ltd；Testosterone propionate is purchased from Tianjin KingYork Amino Acid Co., Ltd.
50 rats are randomly divided into 5 groups by medication: Normal group, model control group, proscar 19.5mg/kg group, compositions 250,500mg/kg group.Except Normal group, other are the group testosterone propionate (7.5mg/Kg) that subcutaneous injection dissolves with olive oil respectively respectively, continuous 12d, Normal group injection olive oil solution, gastric infusion after every day subcutaneous injection 30min, Normal group and model group such as give at the distilled water of capacity, and after last administration, 24h weighs execution on an empty stomach.
The mensuration mice etherization of serum testosterone (T), Culling heart blood, it is placed in the centrifuge tube that heparin processed with the centrifugal 5min of 5000r/min, separated plasma, measures for level of serum testosterone.Serum testosterone adopts liquid equilibrium competition radio immunoassay to measure.125Binding site on I labelled antigen Ag competition limitation antibody A b.In sample, the concentration of Ag and Ag-Ab complex are the functional relationship of negative correlation, and show on dose-effect curve, with this curve for according to can sample be carried out quantitatively.Separating medium is for free phase and the separation in conjunction with phase.Computing formula is (standard pipe cpm value-NSB pipe cpm value)/(zero standard pipe cpm value-NSB pipe cpm value)
The compositions impact on prostatic hyperplasia
Compare with model group, * P < 0.05, * * P < 0.01
Result is compared with Normal group, and model group mouse prostate weight in wet base and prostate index substantially increase, and level of serum testosterone significantly raises, and modeling success is described.Bring out compared with mouse prostate model of hyperplasia group with Testosterone Propionate, compositions heavy dose group can substantially reduce mouse prostate weight and prostate index (P < 0.01).Additionally, the large and small dosage group of compositions extract can improve the rising of mice serum testosterone levels significantly, and present certain dose-effect relationship.
Test example 2 carrageenan-induced rat prostatitis is tested
The male cleaning grade SD rat of laboratory animal 7 week old, weight 200～250g, raising temperature 23 DEG C ± 2 DEG C, lighting hours 12h/d (7: 00～19: 00), adaptability is tested after raising one week.
Reagent QIANLIEKANG, purchased from Zhejiang Kang Enbei pharmaceutical Co. Ltd；Carrageenin, for SIG-MA Products
50 rats are randomly divided into 5 groups by medication: Normal group, model control group, QIANLIEKANG 500mg/kg group, compositions 250,500mg/kg group.Compositions high and low dose group and QIANLIEKANG administration group rat with 10mg/kg gavage, 1 time/d, continuous 9d.Normal group and model control group give isometric(al) aqueous solution.Carry out after 7th administration 1h anaesthetizing and aseptic operation operation: 3% pentobarbital sodium is with after 1.5mg/kg intraperitoneal injection of anesthesia rat, at hypogastrium median incision 1cm under aseptic condition, it is proposed to bladder and both sides seminal vesicle, exposes the prostate notopodium invested inside seminal vesicle.1% carrageenin with 0.2 μm of filter membrane sterilizing is injected separately in prostate bilateral notopodium with the dosage of 0.1ml/, then bladder is resetted and layer-by-layer suture.Post operation continues gavage 2d, after last administration 1h, is put to death by animal and measures prostatitis index.
The determination experiment animal of leukocyte (WBC) sum and lecithin density wins prostate after etherization, accurately weighs 50mg and adds 200 μ L physiology salt, 200 order net filtrations after grinding in manual glass homogenizer.Eddy mixer after fully mixing take 20 μ L, adds 380 μ L leukocyte diluents, under optical microscope, count leukocyte count and observe lecithin density.Measuring and be divided into 4 grades by Clinical Laboratory Standards, namely expiring the visual field is 4 grades, and 3/4 visual field is 3 grades, and 1/2 visual field is 2 grades, and 1/4 visual field is 1 grade.
Prostatic fraction of serum acid phosphatase determination of activity, by rat under etherization Culling heart blood and after standing 1h, separates serum with the centrifugal 15min of 3000r/min under 4 DEG C of conditions and measures prostate acid phosphatase activity in serum.β prostatic fraction of serum acid phosphatase activity uses prostate acid phosphatase testing cassete to measure.
Zn content measure by 10% prostata tissue homogenate 4 DEG C with the centrifugal 10min of 3000r/min after, after taking homogenate supernatant distilled water diluting 10 times, use TAS-990 atomic absorption spectrophotometer to detect and adopt standard curve method to calculate the Zn content in prostata tissue homogenate.
The mensuration of prostata tissue malonaldehyde (MDA) level takes prostata tissue, makes the tissue homogenate of 10% with 0.9% normal saline, and 12000r/min is centrifuged 15min, after, supernatant is for the mensuration of MDA level.Utilize the malonaldehyde (MDA) in lipid peroxide catabolite can form red product with thiobarbituricacidα-condensation, have the character of maximum absorption band at 532nm place, be measured by thiobarbituric acid reaction thing (TBARS) colorimetry.
The mensuration of prostata tissue ORAC (ORAC) adds phosphate buffer in 96 orifice plates, add 6% perchloric acid Deproteinization blood plasma 20 μ L again, then AAPH140 μ L and buffer 20 μ L it is sequentially added into, add 20 μ Ldisodiumfluorescein and start reaction, 96 orifice plates are placed in the fluorescence microplate reader that temperature conditions is 37 DEG C are measured rapidly.Its principle be fluorescent material disodiumfluorescein under 485nm light excites, launch 527nm fluorescence, it is possible to by can be discharged peroxy radical AAPH oxidation and make fluorescent characteristic disappear.When antioxidant exists, with disodiumfluorescein competitive oxidation agent, the speed that its fluorescence disappears can be slowed down.According to this characteristic, sample oxygen radical removing activity can be measured.
In blood plasma, the mensuration of NO level adopts Griess reagent color developing method to measure serum NO level- 3/NO- 2Content represent the concentration of serum NO level.Take 10% tissue homogenate sample of 40 μ l, add Griess reagent (0.05% naphthodiamide of 160 μ l, stand 20min, 550nm wavelength after 0.5% sulfanilamide and 2.5% phosphoric acid 2 and measure solution optical density value (OD) value, calculate NO content according to NO standard curve.The sodium nitrite PBS solution 40 μ l of variable concentrations is added in 160 μ lGriess reagent by being prepared by of NO standard curve, mixing, and after standing 20min, 550nm wavelength measures solution optical density value (OD).With sodium nitrite for abscissa, surveyed OD value is vertical coordinate, makes (NO-)-OD standard curve.
Statistical procedures experimental data represents with x ± s, carries out statistical procedures with Studentt-test inspection, and P < 0.05 is statistically significant.
Carrageenan-induced rat prostatitis test (x ± s, n=10)
Note: compare with matched group, #P < 0.05, ##P < 0.01；Compare with model group, * P < 0.05, * * P < 0.01
It is as shown in the table for result, and compared with carrageenan-induced rat prostatitis model group, high and low dose compositions significantly improves lecithin density in rat prostate liquid (P < 0.01), reduces leukocyte (WBC) sum.When inquiring into prostate acid phosphatase activity change in Zn content and serum in prostata tissue homogenate, it has been found that carrageenin can substantially increase prostatic fraction of serum acid phosphatase activity in substantially reducing prostata tissue while Zn content.Compositions can be effectively improved Zn content in rat prostate tissue, is obviously improved prostatic fraction of serum acid phosphatase activity, and presents certain dose-effect relationship.Inquiring into compositions confirming when affecting rat blood serum and prostata tissue oxidative stress status, compared with model group, compositions can effectively reduce rat blood serum and prostata tissue MDA level, alleviate the rat prostate tissue ORAC ORAC level decline that carrageenin causes, and there is certain dose-effect relationship.
Test example 3 anti-prostate cancer is tested
Anti-prostate cancer test adopts the MIT method of antitumor drug experimental technique, takes the stable human prostata cancer PC-3 cell of Secondary Culture and adjusts through counting, cell density 1 × 105/ ml, is inoculated in 96 well culture plates, every porocyte suspension 200 μ l, CO2To compositions intervention after cultivation 24h in incubator. group technology: 0.25mg/ml, 0.50mg/ml, 1.00mg/ml, 2.00mg/ml, 4.00mg/ml5 concentration combination thing group is set according to composition concentration, and PC-3 cell controls group is set, often organize each 5 repeating holes.Continue to cultivate 48h, MMT method microplate reader 492nm wavelength after adding compositions and measure cell viability (proliferation inhibition rate computing formula: (compositions group, matched group OD value all deduct the OD value correction of zeroing hole in cell proliferation inhibition rate=matched group OD value-compositions group OD value/matched group OD value × 100%..
| Concentration (mg/ml) | OD value | Suppression ratio (%) |
| 0.25 | 0.422±0.011 | 32.8 |
| 0.50 | 0.364±0.012 | 38.7 |
| 1.00 | 0.211±0.011 | 66.5 |
| 2.00 | 0.092±0.007 | 86.4 |
| 4.00 | 0.023±0.006 | 96.5 |
Result shows, compositions all suppresses proliferation of human prostate carcinoma PC-3 cell with dosage-dependent manner, proliferation inhibition rate increases with compositions liquor strength and increases, when compositions same concentrations, the inhibitory action of prostate cancer cell proliferation is compared, difference statistically significant (P < 0.01)
Test example 4 clinical observation material
Clinical observation, adult takes the compositions of the present invention, accidental gastrointestinal upset person, does not generally affect continual cure.The total effective rate of compositions treatment prostatitis 200 example of the present invention is 96.3%, clinical observation is evident in efficacy to the improvement of its main disease, effective percentage such as pudendum distending pain, lower abdomen contracture, waist dull pain and dribbling urination, puckery pain all reaches more than 90%, compare with matched group, significant difference (P < 0.01)；To prostate local sign curative effect, the effective percentage of as firmly tough in body of gland and tenderness respectively 71.7% and 91.8%, hence it is evident that be better than matched group, two groups of comparing differences notable (P < 0.01)；Reduce prostatic fluid leukocyte count, increase lecithin aspect, compositions group effective percentage respectively 95.0% and 92.8%, matched group respectively 58.9% and 56.1%, the two comparing difference notable (P < 0.01)；In prostate ultrasound diagnosis, compositions group effective percentage is substantially better than matched group, and two groups are compared, significant difference (P < 0.01).
Compositions treatment prostatic hyperplasia 150 example of the present invention, overall clinical efficacy rate reaches 87.4%, to improving that main disease such as the nocturia frequency, the sound of rain pattering of prostatic hyperplasia are clean, urinate not the total effective rate such as smooth, difficulty and pain in micturition all more than 85.0%, it is substantially better than matched group, two groups of contrast differences notable (P < 0.01)；Prostate local sign such as prostate increases, matter is hard, tough, the curative effect of disappearence of central groove, composition component is not 42.2%, 54.7%, 52.2%, matched group respectively 23.2%, 19.7%, 21.8%, compositions group is substantially better than matched group, two groups are compared, significant difference (P < 0.01)；Prostate ultrasound diagnosis result, in prostate size, residual urine volume aspect, treatment group curative effect is superior to matched group, and significant difference (P < 0.01), each parameter value results contrast of urinary flow before and after two groups of treatments, in Qmax, AFR, compositions group is superior to matched group, the two comparing difference notable (P < 0.01).From clinical test results, the compositions treatment prostatitis of the present invention, prostatic hyperplasia show that its curative effect is comparatively satisfied.
Claims (10)
1. the compositions treating and preventing prostatosis, it is characterised in that it comprises the raw material of following weight: Saw Palmetto P.E 200～800 parts, Fructus Lycopersici esculenti extract 30～180 parts, soybean extract 30～90 parts.
2. compositions according to claim 1, it is characterised in that: compositions also comprises Fructus Momordicae extract 10-40 part.
3. compositions according to claim 2, it is characterized in that: Saw Palmetto P.E is 600 parts, Fructus Lycopersici esculenti extract is 120 parts, soybean extract is 60 parts, Fructus Momordicae extract 20 parts, it is preferable that it is 600mg that a compositions contains Saw Palmetto P.E, and Fructus Lycopersici esculenti extract is 120mg, soybean extract is 60mg, Fructus Momordicae extract 20mg.
4. compositions according to claim 1, it is characterized in that: Saw Palmetto P.E is 320 parts, Fructus Lycopersici esculenti extract is 50 parts, and soybean extract is 62.5 parts, it is preferable that a compositions contains Saw Palmetto P.E 320mg, Fructus Lycopersici esculenti extract 50mg, soybean extract 62.5mg.
5. compositions according to claim 1, it is characterised in that: described Saw Palmetto P.E is prepared gained by following methods, after sabal raw material is cleaned, ambient ground；Cross 40-60 mesh sieve, weigh the sabal raw material pulverized in advance in extraction kettle, extraction kettle, separating still are respectively heated, reach to set extraction kettle 40 DEG C, the temperature that separating still is 25 DEG C, CO2 enters liquefaction tank liquor through gas purifier, extraction kettle squeezed into by preheated device, depurator, extraction kettle and separating still are boosted, after reaching required extraction kettle pressure 20MPa, separating still pressure 5MPa, closes dioxide bottle, start the cycle over extraction, collecting separating still discharging, dry to obtain Saw Palmetto P.E, in described Saw Palmetto P.E, content of fatty acid is 45%.
6. compositions according to claim 1, it is characterized in that: described Fructus Lycopersici esculenti extract is prepared gained by following methods, raw tomatoes material is pulled an oar, and squeeze and filter, it is dried by vacuum freezing effect, ambient ground, cross 20-40 mesh sieve, powder and hexane weight ratio (1:2) are put into extracting tank and forms intimate mixing, the dissolution from hexane of the pigment in raw material, separating hexane, the raw material of pretreatment enters extraction kettle；CO2 enters liquefaction tank liquor through gas purifier, then extraction kettle is squeezed into by the preheated device of high-pressure plunger pump, depurator, extraction kettle boosts to 30MPa and makes supercritical fluid, set separating still pressure 5MPa, CO2 enters liquefaction groove cycling extraction after device purified separating still, and extract is released from the bottom of separating still, collects separating still discharging, drying to obtain Fructus Lycopersici esculenti extract, in described Fructus Lycopersici esculenti extract, the content of lycopene is 10%.
7. compositions according to claim 1, it is characterised in that described soybean extract is prepared gained by following methods, by Semen sojae atricolor ungrease treatment, pulverizes totally dry defatted soybean with pulverizer, crosses 20-40 mesh sieve, obtain coarse powder；Take and pulverize dry Semen sojae atricolor, add 70% ethanol (volume/weight) of 15 times amount, extract 1 hour 50 DEG C of room temperatures, filter, repeat 2 times, united extraction liquid, employing polyamide is chromatography media, and column chromatography is to extract refining, acetone extract eluent, dry extract, obtains soybean extract, and the content of described Isoflavone in Extract of Soybean is 40%.
8. compositions according to claim 1, it is characterised in that described Fructus Momordicae extract is prepared gained by following methods: first smashed to pieces by Fructus Momordicae fresh fruit, throws to extractor.Adding 3 times amount deionized waters for 1st time, heating, to boiling, is incubated 2h, starts timing from boiling, feed liquid is put into storage tank；Add 3 times amount deionized waters, ebuillition of heated for 2nd time, after insulation 2h, feed liquid is merged with the 1st feed liquid.Being poured into by the extracting solution of merging in concentrator and carry out concentrating under reduced pressure, temperature controls below 60 DEG C, and vacuum degree control, more than 0.08, is recycled to concentrated solution and raw material ratio when being 2.5:1, stops heating, release concentrated solution, cooling.Mateiral pump on microfiltration equipment is started, in concentrated solution suction tube type filter membrance, force (forcing) pump will be started, regulate pressure to 0.2MPa, collect the filtrate through tube type filter membrance, the solution to be concentrated water-dialyzing by 0.5 times will be added time complete, the dialysis solution being collected by, merging filtrate.The filtrate of collection is poured in the storage tank of ultrafiltration apparatus, open the force (forcing) pump of ultrafiltration apparatus, regulate pressure at 1MPa, filtrate retains, by passing through, the film that relative molecular mass is 40000, collect through filtrate, when filtrate is passed through less, slowly add the water-dialyzing of people 0.5 times, collect the dialysis filtrate passed through, merging filtrate.Filtrate being carried out spray drying, obtains Fructus Momordicae extract, in described Fructus Momordicae extract, mogroside content is 25%.
9. the compositions according to claim 1 purposes in preparation treatment prostatic hyperplasia, prostatitis, prostate cancer disease preparation.
10. the preparation that prepared by compositions according to claim 1, it is characterised in that described preparation is ordinary tablet, chewable tablet, buccal tablet, dispersible tablet, oral liquid, granule, powder, soft capsule, hard capsule, unguentum and tincture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410836220.8A CN105796803A (en) | 2014-12-30 | 2014-12-30 | Traditional Chinese medicine composition for treating and preventing prostatic diseases and its preparation method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410836220.8A CN105796803A (en) | 2014-12-30 | 2014-12-30 | Traditional Chinese medicine composition for treating and preventing prostatic diseases and its preparation method and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105796803A true CN105796803A (en) | 2016-07-27 |
Family
ID=56980732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410836220.8A Pending CN105796803A (en) | 2014-12-30 | 2014-12-30 | Traditional Chinese medicine composition for treating and preventing prostatic diseases and its preparation method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105796803A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021069590A1 (en) | 2019-10-10 | 2021-04-15 | Capsugel France SAS | Gelatin capsules with ground calcium carbonate |
| US11517535B2 (en) | 2018-05-14 | 2022-12-06 | Capsugel Belgium Nv | Capsules with opacifier |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0250953A1 (en) * | 1986-06-17 | 1988-01-07 | INDENA S.p.A. | Process for the extraction of oily fruits |
| CN1436786A (en) * | 2003-03-07 | 2003-08-20 | 桂林莱茵生物制品有限公司 | Extraction process of mangosteen glycoside from mangosteen |
| CN1456558A (en) * | 2002-05-10 | 2003-11-19 | 九台市东山粮库贸易部 | Method for extracting soybean isoflavone |
| CN101838178A (en) * | 2010-02-02 | 2010-09-22 | 烟台开发区绿源生物工程有限公司 | Preparation method of lycopene |
| CN102112141A (en) * | 2008-07-31 | 2011-06-29 | 希格马托制药工业公司 | Compositions for preventing or slowing the progression of prostate cancer |
| CN102178808A (en) * | 2011-04-22 | 2011-09-14 | 武汉金锯叶生物科技有限公司 | Medicine for adjunctively treating prostatic disease |
-
2014
- 2014-12-30 CN CN201410836220.8A patent/CN105796803A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0250953A1 (en) * | 1986-06-17 | 1988-01-07 | INDENA S.p.A. | Process for the extraction of oily fruits |
| CN1456558A (en) * | 2002-05-10 | 2003-11-19 | 九台市东山粮库贸易部 | Method for extracting soybean isoflavone |
| CN1436786A (en) * | 2003-03-07 | 2003-08-20 | 桂林莱茵生物制品有限公司 | Extraction process of mangosteen glycoside from mangosteen |
| CN102112141A (en) * | 2008-07-31 | 2011-06-29 | 希格马托制药工业公司 | Compositions for preventing or slowing the progression of prostate cancer |
| CN101838178A (en) * | 2010-02-02 | 2010-09-22 | 烟台开发区绿源生物工程有限公司 | Preparation method of lycopene |
| CN102178808A (en) * | 2011-04-22 | 2011-09-14 | 武汉金锯叶生物科技有限公司 | Medicine for adjunctively treating prostatic disease |
Non-Patent Citations (4)
| Title |
|---|
| 于新: "《天然食品添加剂》", 31 March 2014, 中国轻工业出版社 * |
| 啊啊啊啊进: "保列健 Palmetto Plus™", 《保列健 PALMETTO PLUS》 * |
| 朱洪法: "《精细化工常用原材料手册》", 31 December 2003, 金盾出版社 * |
| 郑健仙: "《功能性食品学》", 30 April 2006, 中国轻工业出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11517535B2 (en) | 2018-05-14 | 2022-12-06 | Capsugel Belgium Nv | Capsules with opacifier |
| US11890383B2 (en) | 2018-05-14 | 2024-02-06 | Capsugel Belgium Nv | Capsules with opacifier |
| WO2021069590A1 (en) | 2019-10-10 | 2021-04-15 | Capsugel France SAS | Gelatin capsules with ground calcium carbonate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104918628A (en) | A drug combination for treating reproductive system cancer and its preparation method | |
| CN104013668A (en) | Application of licoflavone extract in preparation of medicine for treating ulcerative colitis | |
| CN115429866B (en) | Traditional Chinese medicine composition for treating cholecystitis and preparation method thereof | |
| CN113713057B (en) | Traditional Chinese medicine composition and application thereof | |
| CN104206594A (en) | Herba Taxilli health-care tea capable of lowering blood pressure and blood lipid and preparation method thereof | |
| CN105535419A (en) | Method for preparing traditional Chinese medicine composition for treating cerebral thrombosis | |
| CN105796803A (en) | Traditional Chinese medicine composition for treating and preventing prostatic diseases and its preparation method and use | |
| KR102127706B1 (en) | Preparation for improving blood circulation comprising mixed oriental medicinal extracts | |
| CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN103933538A (en) | Medicine for treating spleen-kidney yang deficiency type cirrhosis ascites and preparation method thereof | |
| CN107412713A (en) | Treat Chinese patent drug, dietetic food and the preparation method of autoimmune and immune related diseases | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| KR20220138397A (en) | Chinese medicine composition and its method and application | |
| CN103169742A (en) | Application of elaeagnus conferta roxb | |
| CN103230486A (en) | Traditional Chinese medicine composition, preparation method thereof, and application thereof in preparing medicines used for treating fatty liver | |
| CN114712458B (en) | Pharmaceutical composition for treating vascular aging of hypertension and preparation method and application thereof | |
| CN104922548A (en) | Chinese herbal preparation for treatment of ascariasis | |
| CN109662967A (en) | A kind of antidepressant and application thereof | |
| CN104286864A (en) | Flatstem milkvetch seed oral liquid for improving immunity and preparation method thereof | |
| CN104800565B (en) | A kind of Chinese medicine and preparation method for the treatment of esophageal carcinoma | |
| CN105055967B (en) | A kind of complex health care product and preparation method with auxiliary hyperglycemic function | |
| CN108478706A (en) | It is a kind of to protect cardiovascular composition and preparation method thereof | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| KR20040043707A (en) | Phamaceutical composition for hepatitis and hepatocaricinoma as pharmaceutical preparations ARTMISIA CAPILLARIS, ARTEMISIAE ASIATICAE HERBA, ULMUS DAVIDIANA VAR, HOVENIA DULCIS THUNB, ALNUS JAPONICA, LPH peptide isloated SOYBEAN DEBRIS-WATER EXTRACT, KOREA RAISIN and FAGOPYRUM ESCULENTUM containing them | |
| CN105168662A (en) | Traditional Chinese medicine preparation for treating kidney stone and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 266107, No. 702, Lu Shan Road, Chengyang District, Shandong, Qingdao 119-101 Applicant after: Huajia clouds (Qingdao) Limited health technology Address before: 266107, Chengyang District, Shandong City, Qingdao Province, Danyang Road, south side of the road Applicant before: QINGDAO JIAYUN HUAHAI HEALTH TECHNOLOGY CO., LTD. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160727 |